financetom
Business
financetom
/
Business
/
Kilroy Realty Q3 FFO, Revenue Fall
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kilroy Realty Q3 FFO, Revenue Fall
Oct 27, 2025 3:28 PM

05:12 PM EDT, 10/27/2025 (MT Newswires) -- Kilroy Realty ( KRC ) reported Q3 funds from operations late Monday of $1.08 per diluted share, down from $1.17 a year earlier.

Analysts polled by FactSet expected $0.97.

Revenue in the three months ended Sept. 30 fell to $279.7 million from $289.9 million a year earlier.

Analysts surveyed by FactSet expected $273.8 million.

The company raised guidance for 2025 Nareit funds from operations to the range of $4.18 to $4.24 a share from $4.05 to $4.15.

Analysts polled by FactSet expect $4.11.

Kilroy Realty ( KRC ) shares rose 4.1% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial
Jun 17, 2025
08:38 AM EDT, 06/17/2025 (MT Newswires) -- Lyell Immunopharma ( LYEL ) said Tuesday its phase 1/2 trial of LYL314 achieved robust clinical responses in patients with large B-cell lymphoma treated in the third- or later-line setting. The trial showed an 88% overall response rate and a 72% complete response rate among 25 evaluable patients, according to Lyell. The company...
ProPhase Labs Announces Successful BE-Smart Test for Detecting Esophageal Cancer; Shares Rise Pre-Bell
ProPhase Labs Announces Successful BE-Smart Test for Detecting Esophageal Cancer; Shares Rise Pre-Bell
Jun 17, 2025
08:38 AM EDT, 06/17/2025 (MT Newswires) -- ProPhase Labs ( PRPH ) said Tuesday its BE-Smart molecular diagnostic test achieved over 95% success in detecting biomarkers linked to esophageal cancer, validating its use with esophageal brush cytology. The test, using a proprietary panel of biomarkers, reliably detects cancer cells, particularly in esophageal adenocarcinoma, a rapidly growing cancer, the company said....
Orthofix Medical Begins Global Rollout of Limb Preservation System TrueLok Elevate
Orthofix Medical Begins Global Rollout of Limb Preservation System TrueLok Elevate
Jun 17, 2025
08:38 AM EDT, 06/17/2025 (MT Newswires) -- Orthofix Medical ( OFIX ) said Tuesday that it has launched a new limb preservation device globally following earlier regulatory clearance. The company said it began commercial distribution of the TrueLok Elevate Transverse Bone Transport System, a device for treating limb defects such as those caused by diabetic ulcers. The system had previously...
Copyright 2023-2026 - www.financetom.com All Rights Reserved